Skip to main content
. Author manuscript; available in PMC: 2010 Aug 24.
Published in final edited form as: Mol Cancer Res. 2008 May;6(5):695–705. doi: 10.1158/1541-7786.MCR-07-0294

FIGURE 5.

FIGURE 5

Smad3 and N-cadherin expression in serous cystadenocarcinoma and relationship to survival. A. Brightfield images (20×) showing immunostaining of Smad3 or N-cadherin assigned a score of 1 or 2 in serous cystadenocarcinoma tissue cores counterstained with hematoxylin; bar, 100 μm. B. Survival curves for serous cystadenocarcinoma patients based on average scores for Smad3 (nuclear) and N-cadherin expression. For Smad3, survival curves were plotted for patients exhibiting low (average score < 1.5) and high (average score ≥ 1.5) nuclear expression (P = 0.0513). For N-cadherin, survival curves were plotted for patients with no (average score = 0) expression, low expression (average score < 1.5), and high expression (average score > 1.5; P = 0.9295). Scores for all tissue cores from each patient were averaged and then subjected to Kaplan-Meier estimate and log-rank test.